^
    10d
    RD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell Malignancies (clinicaltrials.gov)
    P1, N=10, Recruiting, Wuhan Union Hospital, China
    New P1 trial
    |
    RD13-02
    1m
    RD13-02 for Patients With r/r CD7+ T Cell Hematologic Malignancies (clinicaltrials.gov)
    P1, N=6, Completed, Henan Cancer Hospital | Recruiting --> Completed | N=10 --> 6 | Trial completion date: Jun 2026 --> Aug 2024 | Trial primary completion date: Jun 2025 --> Aug 2024
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    CD7 (CD7 Molecule)
    |
    RD13-02
    1m
    RD13-02 CAR-T Cell Injection for Patients With r/r CD7+ T-ALL/T-LBL (clinicaltrials.gov)
    P1, N=4, Completed, Xiaoyu Zhu | Recruiting --> Completed | N=12 --> 4 | Trial completion date: Apr 2025 --> Aug 2024 | Trial primary completion date: Apr 2024 --> Aug 2024
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    CD7 (CD7 Molecule)
    |
    RD13-02
    1m
    Research Development（RD）13-02 Chimeric Antigen Receptor(CAR) -T Cell Injection for Patients With r/r Cluster Of Differentiation 7（CD7）+ T-Acute Lymphoblastic Leukemia(ALL)/T-Lymphoblastic Lymphoma(LBL) /Acute Myelogenous Leukemia(AML) (clinicaltrials.gov)
    P1, N=8, Completed, Kai Lin Xu，MD | Recruiting --> Completed | N=18 --> 8 | Trial completion date: Mar 2025 --> Aug 2024 | Trial primary completion date: Mar 2024 --> Aug 2024
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    CD7 (CD7 Molecule)
    |
    RD13-02
    1m
    BHCT-RD13-02-02: CD7 CAR-T for Patients With r/r CD7+ T-ALL/T-LBL (clinicaltrials.gov)
    P1, N=20, Completed, He Huang | Recruiting --> Completed | Trial completion date: May 2025 --> Aug 2024 | Trial primary completion date: Mar 2024 --> Aug 2024
    Trial completion • Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    CD7 (CD7 Molecule)
    |
    RD13-02
    3ms
    CD7 CAR T Cells (RD13-02) in the Treatment of Relapsed/Refractory Severe Aplastic Anemia (clinicaltrials.gov)
    P1, N=15, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New P1 trial
    |
    cyclophosphamide • RD13-02
    over1year
    Clinical Study of CD7 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory CD7-positive Peripheral T Cell Lymphoma (clinicaltrials.gov)
    P1, N=35, Not yet recruiting, Zhao Weili
    New P1 trial • CAR T-Cell Therapy
    |
    CD7 (CD7 Molecule)
    |
    RD13-02
    over1year
    RD13-02 for Patients With r/r CD7+ T Cell Hematologic Malignancies (clinicaltrials.gov)
    P1, N=10, Recruiting, Henan Cancer Hospital
    New P1 trial
    |
    CD7 (CD7 Molecule)
    |
    RD13-02
    over1year
    Research Development（RD）13-02 Chimeric Antigen Receptor(CAR) -T Cell Injection for Patients With r/r Cluster Of Differentiation 7（CD7）+ T-Acute Lymphoblastic Leukemia(ALL)/T-Lymphoblastic Lymphoma(LBL) /Acute Myelogenous Leukemia(AML) (clinicaltrials.gov)
    P1, N=18, Recruiting, Kai Lin Xu，MD
    New P1 trial • CAR T-Cell Therapy
    |
    CD7 (CD7 Molecule)
    |
    RD13-02
    over1year
    RD13-02 CAR-T Cell Injection for Patients With r/r CD7+ T-ALL/T-LBL (clinicaltrials.gov)
    P1, N=12, Recruiting, Xiaoyu Zhu
    New P1 trial • CAR T-Cell Therapy
    |
    CD7 (CD7 Molecule)
    |
    RD13-02
    over1year
    Research Development13(RD13)-02 Cell Injection in Patients With Relapsed or Refractory Cluster Of Differentiation 7(CD7)-Positive Hematological Malignancies (clinicaltrials.gov)
    P1, N=18, Recruiting, MEI HENG
    New P1 trial
    |
    CD7 (CD7 Molecule)
    |
    RD13-02
    almost2years
    CD7 CAR-T for Patients With r/r CD7+ T-ALL/T-LBL (clinicaltrials.gov)
    P1, N=22, Recruiting, He Huang
    New P1 trial • CAR T-Cell Therapy
    |
    CD7 (CD7 Molecule)
    |
    RD13-02